152 related articles for article (PubMed ID: 37759311)
1. Development of a high-affinity anti-bovine PD-1 rabbit-bovine chimeric antibody using an efficient selection and large production system.
Okagawa T; Konnai S; Goto S; Sajiki Y; Ganbaatar O; Watari K; Nakamura H; Wang CX; Tachibana T; Kato Y; Kameda Y; Kohara J; Terasaki N; Kubota M; Takeda A; Takahashi H; Suzuki Y; Maekawa N; Murata S; Ohashi K
Vet Res; 2023 Sep; 54(1):82. PubMed ID: 37759311
[TBL] [Abstract][Full Text] [Related]
2. Anti-Bovine Programmed Death-1 Rat-Bovine Chimeric Antibody for Immunotherapy of Bovine Leukemia Virus Infection in Cattle.
Okagawa T; Konnai S; Nishimori A; Maekawa N; Ikebuchi R; Goto S; Nakajima C; Kohara J; Ogasawara S; Kato Y; Suzuki Y; Murata S; Ohashi K
Front Immunol; 2017; 8():650. PubMed ID: 28638381
[TBL] [Abstract][Full Text] [Related]
3. Increase of cells expressing PD-1 and PD-L1 and enhancement of IFN-γ production via PD-1/PD-L1 blockade in bovine mycoplasmosis.
Goto S; Konnai S; Okagawa T; Nishimori A; Maekawa N; Gondaira S; Higuchi H; Koiwa M; Tajima M; Kohara J; Ogasawara S; Kato Y; Suzuki Y; Murata S; Ohashi K
Immun Inflamm Dis; 2017 Sep; 5(3):355-363. PubMed ID: 28544524
[TBL] [Abstract][Full Text] [Related]
4. Combined Immune Checkpoint Blockade Enhances Antiviral Immunity against Bovine Leukemia Virus.
Nakamura H; Konnai S; Okagawa T; Maekawa N; Sajiki Y; Watari K; Kamitani K; Saito M; Kato Y; Suzuki Y; Murata S; Ohashi K
J Virol; 2023 Jan; 97(1):e0143022. PubMed ID: 36598199
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo antivirus activity of an anti-programmed death-ligand 1 (PD-L1) rat-bovine chimeric antibody against bovine leukemia virus infection.
Nishimori A; Konnai S; Okagawa T; Maekawa N; Ikebuchi R; Goto S; Sajiki Y; Suzuki Y; Kohara J; Ogasawara S; Kato Y; Murata S; Ohashi K
PLoS One; 2017; 12(4):e0174916. PubMed ID: 28445479
[TBL] [Abstract][Full Text] [Related]
6. Increase of cells expressing PD-L1 in bovine leukemia virus infection and enhancement of anti-viral immune responses in vitro via PD-L1 blockade.
Ikebuchi R; Konnai S; Shirai T; Sunden Y; Murata S; Onuma M; Ohashi K
Vet Res; 2011 Sep; 42(1):103. PubMed ID: 21943148
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of interleukin-2 production by bovine peripheral blood mononuclear cells treated with the combination of anti-programmed death-ligand 1 and cytotoxic T lymphocyte antigen 4 chimeric monoclonal antibodies.
Watari K; Konnai S; Okagawa T; Maekawa N; Sajiki Y; Kato Y; Suzuki Y; Murata S; Ohashi K
J Vet Med Sci; 2022 Jan; 84(1):6-15. PubMed ID: 34789592
[TBL] [Abstract][Full Text] [Related]
8. Development of anti-feline PD-1 antibody and its functional analysis.
Nishibori S; Kaneko MK; Nakagawa T; Nishigaki K; Kato Y; Igase M; Mizuno T
Sci Rep; 2023 Apr; 13(1):6420. PubMed ID: 37095139
[TBL] [Abstract][Full Text] [Related]
9. Programmed death-ligand 1 expression in swine chronic infections and enhancement of interleukin-2 production via programmed death-1/programmed death-ligand 1 blockade.
Ganbaatar O; Konnai S; Okagawa T; Nojima Y; Maekawa N; Ichikawa Y; Kobayashi A; Shibahara T; Yanagawa Y; Higuchi H; Kato Y; Suzuki Y; Murata S; Ohashi K
Immun Inflamm Dis; 2021 Dec; 9(4):1573-1583. PubMed ID: 34414683
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of immunoinhibitory factors PD-1/PD-L1 in sheep.
Tiyamanee W; Konnai S; Okagawa T; Nojima Y; Ganbaatar O; Maekawa N; Hasebe R; Kagawa Y; Kato Y; Suzuki Y; Murata S; Ohashi K
Vet Immunol Immunopathol; 2023 Jul; 261():110609. PubMed ID: 37201379
[TBL] [Abstract][Full Text] [Related]
11. Influence of PD-L1 cross-linking on cell death in PD-L1-expressing cell lines and bovine lymphocytes.
Ikebuchi R; Konnai S; Okagawa T; Yokoyama K; Nakajima C; Suzuki Y; Murata S; Ohashi K
Immunology; 2014 Aug; 142(4):551-61. PubMed ID: 24405267
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of bovine programmed death-ligand 2.
Nishimori A; Konnai S; Ikebuchi R; Okagawa T; Nakajima C; Suzuki Y; Mingala CN; Murata S; Ohashi K
Microbiol Immunol; 2014 Jul; 58(7):388-97. PubMed ID: 24845976
[TBL] [Abstract][Full Text] [Related]
13. Blockade of bovine PD-1 increases T cell function and inhibits bovine leukemia virus expression in B cells in vitro.
Ikebuchi R; Konnai S; Okagawa T; Yokoyama K; Nakajima C; Suzuki Y; Murata S; Ohashi K
Vet Res; 2013 Jul; 44(1):59. PubMed ID: 23876077
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade.
Ganbaatar O; Konnai S; Okagawa T; Nojima Y; Maekawa N; Minato E; Kobayashi A; Ando R; Sasaki N; Miyakoshi D; Ichii O; Kato Y; Suzuki Y; Murata S; Ohashi K
PLoS One; 2020; 15(11):e0234218. PubMed ID: 33216754
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 upregulation by IFN-α/γ-mediated Stat1 suppresses anti-HBV T cell response.
Liu L; Hou J; Xu Y; Qin L; Liu W; Zhang H; Li Y; Chen M; Deng M; Zhao B; Hu J; Zheng H; Li C; Meng S
PLoS One; 2020; 15(7):e0228302. PubMed ID: 32628668
[TBL] [Abstract][Full Text] [Related]
16. Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses.
Zettl M; Wurm M; Schaaf O; Mostböck S; Tirapu I; Apfler I; Lorenz IC; Frego L; Kenny C; Thibodeau M; Oquendo Cifuentes E; Reschke M; Moll J; Kraut N; Vogt A; Sedgwick JD; Waizenegger IC
Oncoimmunology; 2022; 11(1):2080328. PubMed ID: 35756842
[TBL] [Abstract][Full Text] [Related]
17. Immune inhibitory function of bovine CTLA-4 and the effects of its blockade in IFN-γ production.
Watari K; Konnai S; Maekawa N; Okagawa T; Suzuki Y; Murata S; Ohashi K
BMC Vet Res; 2019 Oct; 15(1):380. PubMed ID: 31665022
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy.
Zhang H; Xia Y; Yu C; Du H; Liu J; Li H; Huang S; Zhu Q; Xu Y; Zou Y
Molecules; 2021 Jun; 26(11):. PubMed ID: 34199417
[TBL] [Abstract][Full Text] [Related]
19. Bispecific antibody targeting both B7-H3 and PD-L1 exhibits superior antitumor activities.
Li HY; Chen YL; Deng XN; Li HH; Tan J; Liu GJ; Zheng YJ; Pei M; Peng KT; Yue LL; Chen XJ; Liu Y; Zhao YS; Wang CH
Acta Pharmacol Sin; 2023 Nov; 44(11):2322-2330. PubMed ID: 37328649
[TBL] [Abstract][Full Text] [Related]
20. Differential impact of PD-1 and/or interleukin-10 blockade on HIV-1-specific CD4 T cell and antigen-presenting cell functions.
Porichis F; Hart MG; Zupkosky J; Barblu L; Kwon DS; McMullen A; Brennan T; Ahmed R; Freeman GJ; Kavanagh DG; Kaufmann DE
J Virol; 2014 Mar; 88(5):2508-18. PubMed ID: 24352453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
